Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2000-8-11
pubmed:abstractText
The present study examines N-myc and c-myc protein expression with Western blotting and single and double-labeling immunohistochemistry in the hippocampus in Alzheimer disease (AD), the striatum in Huntington disease (HD) and the substantia nigra in Parkinson disease (PD). No modifications in the N-myc and c-myc expression are found in hippocampal neurons in AD, striatal neurons in HD, and pigmented neurons of the substantia nigra in PD. Yet punctate synaptic-like N-myc immunoreactivity, matching enhanced synaptophysin expression, occurs in diffuse plaques, but not in dystrophic neurites of neuritic plaques. In contrast, c-myc immunoreactivity is found in dystrophic neurites, but not in aberrant sproutings of neuritic plaques, as shown by double-labeling immunohistochemistry to c-myc and phosphorylated tau or phosphorylated neurofilament epitopes, and to c-myc and GAP-43, respectively. Strong N-myc and c-myc are observed in reactive astrocytes in AD, HD and PD, as revealed by double-labeling with N-myc or c-myc and GFAP. Finally, no relationship is found between nuclear DNA fragmentation and increased N-myc or c-myc expression in individual cells. These results demonstrate that neuron death in AD, HD and PD is not associated with modifications in the steady-state expression of N-myc and c-myc in individual neurons, and that neurofibrillary degeneration and Lewy body formation are not accompanied by increased immunoreactivity to these transcription factors. Increased N-myc and c-myc expression in reactive astrocytes probably plays a role in reactive astrocytosis in human neurodegenerative disorders.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0169-328X
pubmed:author
pubmed:issnType
Print
pubmed:day
5
pubmed:volume
77
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
270-6
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:10837922-Aged, pubmed-meshheading:10837922-Aged, 80 and over, pubmed-meshheading:10837922-Alzheimer Disease, pubmed-meshheading:10837922-Astrocytes, pubmed-meshheading:10837922-Blotting, Western, pubmed-meshheading:10837922-Brain, pubmed-meshheading:10837922-Cell Death, pubmed-meshheading:10837922-DNA Fragmentation, pubmed-meshheading:10837922-Female, pubmed-meshheading:10837922-Gliosis, pubmed-meshheading:10837922-Hippocampus, pubmed-meshheading:10837922-Humans, pubmed-meshheading:10837922-Huntington Disease, pubmed-meshheading:10837922-Immunohistochemistry, pubmed-meshheading:10837922-Male, pubmed-meshheading:10837922-Neostriatum, pubmed-meshheading:10837922-Parkinson Disease, pubmed-meshheading:10837922-Plaque, Amyloid, pubmed-meshheading:10837922-Proto-Oncogene Proteins c-myc, pubmed-meshheading:10837922-Substantia Nigra
pubmed:year
2000
pubmed:articleTitle
N-myc and c-myc expression in Alzheimer disease, Huntington disease and Parkinson disease.
pubmed:affiliation
Unitat de Neuropatologia, Servei d'Anatomia Patològica, Hospital Princeps d'Espanya, i Departament de Biologia Cel.lular i Anatomia Patològica, Facultat de Medicina, Universitat de Barcelona, Hospitalet de Llobregat, Llobregat, Spain. iferrer@sakma.es
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't